Verve Therapeutics Stock Analysis
| VERV Stock | USD 5.55 0.01 0.18% |
Verve Therapeutics is overvalued with Real Value of 5.06 and Target Price of 24.48. The main objective of Verve Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Verve Therapeutics is worth, separate from its market price. There are two main types of Verve Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Verve Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Verve Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Verve Stock trading window is adjusted to America/New York timezone.
Verve |
Verve Stock Analysis Notes
About 90.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.0. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Verve Therapeutics recorded a loss per share of 2.35. The entity had not issued any dividends in recent years. Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Verve Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 113 people. For more information please call Sekar MD at 617 603 0070 or visit https://www.vervetx.com.Verve Therapeutics Investment Alerts
| Verve Therapeutics had very high historical volatility over the last 90 days | |
| Verve Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 32.33 M. Net Loss for the year was (198.71 M) with profit before overhead, payroll, taxes, and interest of 9.48 M. | |
| Verve Therapeutics currently holds about 293.56 M in cash with (157.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9. | |
| Over 90.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: RBC Cuts Price Target on Verve Therapeutics to 15 From 17, Keeps Outperform, Speculative Risk - Marketscreener.com |
Verve Therapeutics Upcoming and Recent Events
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Verve Largest EPS Surprises
Earnings surprises can significantly impact Verve Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.6617 | -0.59 | 0.0717 | 10 | ||
2023-03-02 | 2022-12-31 | -0.76 | -0.67 | 0.09 | 11 | ||
2025-02-27 | 2024-12-31 | -0.6705 | -0.58 | 0.0905 | 13 |
Verve Therapeutics Environmental, Social, and Governance (ESG) Scores
Verve Therapeutics' ESG score is a quantitative measure that evaluates Verve Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Verve Therapeutics' operations that may have significant financial implications and affect Verve Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Verve Therapeutics Thematic Classifications
In addition to having Verve Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
Verve Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 1.8 M | Baker Bros Advisors Lp | 2024-12-31 | 1.7 M | Geode Capital Management, Llc | 2024-12-31 | 1.6 M | Fmr Inc | 2024-12-31 | 1.4 M | Point72 Asset Management, L.p. | 2024-12-31 | 1.4 M | Redmile Group, Llc | 2024-12-31 | 1.3 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.3 M | Ecor1 Capital, Llc | 2024-12-31 | 1.2 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 798.9 K | Alphabet Inc | 2024-12-31 | 12.3 M | Blackrock Inc | 2024-12-31 | 7.5 M |
Verve Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 492.82 M.Verve Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | (0.40) | (0.38) |
Management Efficiency
Verve Therapeutics has return on total asset (ROA) of (0.2042) % which means that it has lost $0.2042 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3636) %, meaning that it created substantial loss on money invested by shareholders. Verve Therapeutics' management efficiency ratios could be used to measure how well Verve Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2025. Return On Capital Employed is likely to drop to -0.4 in 2025. At this time, Verve Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 8.3 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 65.9 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.86 | 4.14 | |
| Tangible Book Value Per Share | 5.86 | 4.14 | |
| Enterprise Value Over EBITDA | (1.63) | (1.71) | |
| Price Book Value Ratio | 0.96 | 1.01 | |
| Enterprise Value Multiple | (1.63) | (1.71) | |
| Price Fair Value | 0.96 | 1.01 | |
| Enterprise Value | 372.5 M | 353.8 M |
The strategic initiatives led by Verve Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 24th of March, Verve Therapeutics has the Risk Adjusted Performance of 0.0264, semi deviation of 5.07, and Coefficient Of Variation of 4947.47. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Verve Therapeutics, as well as the relationship between them. Please validate Verve Therapeutics jensen alpha and semi variance to decide if Verve Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 5.55 per share. Given that Verve Therapeutics has jensen alpha of 0.2319, we advise you to double-check Verve Therapeutics's current market performance to make sure the company can sustain itself at a future point.Verve Therapeutics Price Movement Analysis
The output start index for this execution was four with a total number of output elements of fifty-seven. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Verve Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Verve Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Verve Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verve Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verve Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Verve Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Verve Therapeutics Outstanding Bonds
Verve Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Verve Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Verve bonds can be classified according to their maturity, which is the date when Verve Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| VERTICAL HOLDCO GMBH Corp BondUS92537VAA89 | View | |
| VERTICAL U S Corp BondUS92537RAA77 | View | |
| US92535UAB08 Corp BondUS92535UAB08 | View |
Verve Therapeutics Predictive Daily Indicators
Verve Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Verve Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Verve Therapeutics Corporate Filings
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 5th of February 2025 Other Reports | ViewVerify | |
| 31st of January 2025 Other Reports | ViewVerify | |
F4 | 10th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 4th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 3rd of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 18th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Verve Therapeutics Forecast Models
Verve Therapeutics' time-series forecasting models are one of many Verve Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Verve Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Verve Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Verve Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Verve shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Verve Therapeutics. By using and applying Verve Stock analysis, traders can create a robust methodology for identifying Verve entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (6.14) | (6.44) | |
| Operating Profit Margin | (7.07) | (7.43) | |
| Net Loss | (6.15) | (6.45) | |
| Gross Profit Margin | 0.48 | 0.51 |
Current Verve Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Verve analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Verve analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 24.48 | Strong Buy | 9 | Odds |
Most Verve analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Verve stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Verve Therapeutics, talking to its executives and customers, or listening to Verve conference calls.
Verve Stock Analysis Indicators
Verve Therapeutics stock analysis indicators help investors evaluate how Verve Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Verve Therapeutics shares will generate the highest return on investment. By understating and applying Verve Therapeutics stock analysis, traders can identify Verve Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 211 M | |
| Common Stock Shares Outstanding | 84.6 M | |
| Total Stockholder Equity | 493.4 M | |
| Tax Provision | 349 K | |
| Property Plant And Equipment Net | 96.7 M | |
| Cash And Short Term Investments | 524.3 M | |
| Cash | 172.6 M | |
| Accounts Payable | 4.5 M | |
| Net Debt | -102.6 M | |
| 50 Day M A | 6.8947 | |
| Total Current Liabilities | 42.9 M | |
| Other Operating Expenses | 261 M | |
| Non Current Assets Total | 104.6 M | |
| Non Currrent Assets Other | 7.9 M | |
| Stock Based Compensation | 43.3 M |
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.